Devyser Diagnostics is pushing deeper into transplant and prenatal genetic testing, betting that wider use by major labs and smoother reimbursement will turn today’s pilots into steady, repeat business. The upside looks tied to regulatory and partner timelines, while cash needs and reliance on a few big channels are the key things to watch.Read more
Devyser Diagnostics is pushing into growing genetic testing markets, but the path to bigger profits may be bumpier than it looks as it keeps spending on research and its U.S. rollout. Heavy reliance on big partners and uncertain reimbursement decisions could slow adoption and keep margins under pressure before longer-term demand shows up.Read more
No trending discussion available.
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.
